Reactivating NK Cells in Treating Refractory Head and Neck Cancer
NCT02507154
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Cancer
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG:
Cetuximab + NK cells
Sponsor
National University Hospital, Singapore